Silo Pharma Inc. has announced the execution of a non-binding Letter of Intent with Allucent (US) LLC, a global clinical research organization. This partnership aims to support the Phase 1 clinical development of SPC-15, Silo Pharma’s intranasal treatment candidate for PTSD and anxiety. Under the proposed collaboration, Allucent will provide comprehensive clinical research services, including clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling, and medical writing, to facilitate the execution and reporting of planned Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies in healthy subjects. The agreement also outlines payment terms, including an upfront service fee and reconciliation of pass-through costs upon project completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9617993) on December 30, 2025, and is solely responsible for the information contained therein.